Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-Label, Multicenter, Controlled Study to Assess Safety and Efficacy of ELAD in Subjects With Alcohol-Induced Liver Decompensation (AILD)

Trial Profile

A Randomized, Open-Label, Multicenter, Controlled Study to Assess Safety and Efficacy of ELAD in Subjects With Alcohol-Induced Liver Decompensation (AILD)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Feb 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Extracorporeal hepatocyte-based therapy (Primary) ; Cell replacements
  • Indications Alcoholic hepatitis; Alcoholic liver disorders; Liver failure
  • Focus Registrational; Therapeutic Use
  • Sponsors Vital Therapies
  • Most Recent Events

    • 05 Jun 2018 New Zealand and Germany were planned locations.
    • 05 Jun 2018 Results of a biomarker analysis presented at the Digestive Disease Week 2018
    • 05 Jun 2018 Results analysing inflammation biomarkers during Elad treatment from studies VTI-208 and VTL-308 presented at the Digestive Disease Week 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top